Safety Monitoring of Influenza A（H1N1）Vaccine in US

Abstract

CLC Number:

WANG Dan, DONG Duo, WANG Ya-li, HOU Yong-fang, WANG Chun-ting, LIU Cui-li. Safety Monitoring of Influenza A（H1N1）Vaccine in US[J]. Chinese Journal of Pharmacovigilance, 2011, 8(12): 725-728.

[1] US CDC. H1N1 Presentation for Immunization Update 2010[EB/OL].2010-07-27[2011-05-12].http://www.cdc.gov/h1n1flu/imm_update_transcript.htm.
[2] US CDC. The 2009 H1N1 Pandemic: Summary Highlights, April 2009-April 2010[EB/OL]. 2010-6-16[2011-05-12].http://www.cdc.gov/h1n1flu/cdcresponse.htm.
[3] HHS. Federal Plans to Monitor Immunization Safety for the Pandemic 2009 H1N1 Influenza Vaccination Program[EB/OL]. [2011-05-12].http://www.flu.gov/professional/federal/monitor_immunization_safety.html.
[4] US CDC. Summary of 2009 Monovalent H1N1 Influenza Vaccine Data Vaccine Adverse Event Reporting System[EB/OL]. 2010-05-29[2011-05-18].http://vaers.hhs.gov/resources/2010H1N1Summary_June03.pdf.
[5] Vellozzi C,. Adverse events following influenza A(H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System[J]. Vaccine.,2010 .28(45):7248-7255.
[6] Board on Population Health and Public Health Practice. Immunization Safety Review: Influenza Vaccines and Neurological Complications[EB/OL]. [2011-05-18]. http://iom.edu/Reports/2003/Immunization-Safety-Review-Influenza-Vaccines-and-Neurological-Complications.aspx.
[7] CDR.药物警戒快讯.[EB/OL].[2011-05-11].http://www.cdr.gov.cn/gxzy/_ywjjkx_/2009n/01/13108.shtml.
[8] US.CDC. Vaccine Safety Datalink(VSD) Project[EB/OL]. http://www.cdc.gov/vaccinesafety/Activities/VSD.html.
[9] VSRAWG. Report on 2009 H1N1 Vaccine Safety Risk Assessment-June 2010[EB/OL]. 2010-07[2011-06-12]. http://www.hhs.gov/nvpo/nvac/reports/vsrawg_repot_may2010.html.
[10] FDA&CDC. Archived Updates[EB/OL]. [2011-06-12].http://vaers.hhs.gov/resources/updates.
[11] 中国疾病预防控制中心. 国疾病预防控制中心充分做好甲型H1N1流感网络直报准备工作[EB/OL].2009-05-02[2011-05-15]. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohwsyjbgs/s9992/200905/40366.htm.
[12] 梁晓峰.中国甲型流感（H1N1）疫苗上市后监测的安全性[N].中国医学论坛报,2011-02-24.

Safety Monitoring of Influenza A（H1N1）Vaccine in US

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

[1]	WU Yingqi, ZHU Ting, TONG Tong, LI Min, SHEN Aizong. Factors related to ADR/ADE of albumin bound paclitaxel [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1123-1127.
[2]	FAN Rong, DONG Duo. Overview and Thoughts on WHO International Drug Monitoring [J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 43-46.
[3]	GAO Jing ,TIAN Ke-ren ,YU Chao, ZHOU Juan, XU Jin ,WAN Kai-hua, LI Sui . A Study o f Drug Safety Monitoring Awareness Assessment Index System for Drug-producing Enterprises Staff Based on Delphi Method [J]. Chinese Journal of Pharmacovigilance, 2013, 10(6): 344-347.
[4]	NING Yan-yang, YANG Yue, WEI Jing. Literature Review of Post-marketing Drug Safety Monitoring in China [J]. Chinese Journal of Pharmacovigilance, 2011, 8(7): 419-421.
[5]	HUANG Chuan-hai, TIAN Yue-jie, LI Pan-hai, LIU Wei, JIN Shao-hong. Study on Standards and Norms of Drug Safety Monitoring Data and Comprehensive Analysis [J]. Chinese Journal of Pharmacovigilance, 2010, 7(1): 25-27.